Industry News
Biotechnology Industry News

Every year, the BIO International…
Every year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ecosystem.
After pausing a controversial…
After pausing a controversial policy to publicly release drug rejection letters in April, the FDA today confirmed that the pause has been lifted and that more documents will be coming down the line.
Biogen leaders took to an investor…
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which, despite slowing cognitive decline on par with approved medicines, sparked a significant stock
Chai Discovery has continued its…
Chai Discovery has continued its whirlwind emergence, closing its third financing round in 11 months to bring its total funding haul above $600 million. The latest round values the startup at $3.8 billion.
Summit Therapeutics has cleared…
Summit Therapeutics has cleared out an asset from its pre-ivonescimab history, offloading the antibiotic drug candidate ridinilazole to the OpenAI-backed startup Biossil for $500,000 upfront.
Avere Therapeutics has burst onto…
Avere Therapeutics has burst onto the scene by securing a public listing via a reverse merger with NextCure, while stocking a pipeline with an IL-23 drug from Hansoh Pharmaceutical.
Biogen’s leading tau-targeting…
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into phase 3 development.
Ohio’s $30M training initiative…
Ohio’s $30M training initiative aims to scale talent pipelines and power life sciences growth statewide.
Merck KGaA’s U.S. research site…
Merck KGaA’s U.S. research site has instituted a new in-office work requirement that may lead to the imminent departure of as many as 70 staffers.
The FDA has published 14 new…
The FDA has published 14 new rejection letters for drug applications, mere days after confirming to Fierce that a policy of releasing the documents had been paused in April.
Spero Therapeutics is pivoting to…
Spero Therapeutics is pivoting to immune and inflammation indications through a license agreement for a CD40L antibody with Innovent Biologics in a deal worth up to $1.1 billion.
The latest phase 2 readout for Q32…
The latest phase 2 readout for Q32 Bio’s alopecia hopeful received a warm reception from investors, supporting the biotech’s case that the drug could offer a more durable alternative to JAK inhibitors.
Agenus has scrapped a phase 3…
Agenus has scrapped a phase 3 study of its combo therapy in colorectal cancer after just three months in order to go all-in on colon cancer.
Pharma platform company China…
Pharma platform company China Medical System Holdings has tapped up existing partner Insilico for a 1.2 billion yuan ($177 million) collaboration aimed at a “mass-market” central nervous system indication.
Apnimed is having sweet dreams of…
Apnimed is having sweet dreams of an IPO that could fund the planned commercial launch of an obstructive sleep apnea therapy that is currently awaiting an FDA approval decision.
Hansoh Pharmaceutical’s pair of…
Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to make them priority programs.
Bausch + Lomb has abandoned its…
Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study.
After Idorsia’s former chief,…
After Idorsia’s former chief, Srishti Gupta, M.D., left the company upon “mutual agreement” in March, the Swiss drugmaker has now tapped a new leader, Roland Wandeler, Ph.D. Wandeler will officially take over from interim CEO
Roche has halted development on…
Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaited new medicines.
“We were not expecting to see…
“We were not expecting to see clinical responses so early,” Vaneet Sandhu, M.D., rheumatologist and vice president of clinical development at Fate Therapeutics, told Fierce.

